Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience

[1]  G. Salles,et al.  Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Mercadal,et al.  Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era , 2019, British journal of haematology.

[3]  J. Cerhan,et al.  Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Giné,et al.  Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era , 2018, British journal of haematology.

[5]  E. Kimby,et al.  Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. , 2018, The Lancet. Haematology.

[6]  Julio Delgado,et al.  Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group , 2017, British journal of haematology.

[7]  E. Kimby,et al.  Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Cerhan,et al.  Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Kimby,et al.  Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study , 2014, Leukemia.

[12]  Summer S. Han,et al.  Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.

[13]  J. Rossi,et al.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.

[14]  R. Marcus,et al.  Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Ayers,et al.  Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[19]  R. Fisher,et al.  New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[22]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[23]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[25]  S. Horning.  Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.

[26]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[27]  S. Horning,et al.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.